

CV Date	16/03/2022
---------	------------

## Part A. PERSONAL INFORMATION

First Name *	Pilar		
Family Name *	Lauzurica Gomez		
Sex *	Female	Date of Birth *	
ID number Social Security, Passport *	656275Q	Phone Number *	(+34) 918223718
URL Web			
Email Address	plauzurica@gmail.com		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0001-6579-1948	
	Researcher ID		
	Scopus Author ID		

\* Mandatory

### A.1. Current position

Job Title	Investigadora Científica		
Starting date	2006		
Institution	Instituto de Salud Carlos III		
Department / Centre	LR Inmunología / Centro Nacional de Microbiología		
Country	Spain	Phone Number	918223718
Keywords			

### A.2. Previous positions

Period	Job Title / Name of Employer / Country
1997 - 2006	Professor and Principal Investigator / Universitat de Barcelona / Spain
1996 - 1997	Fellow Reinstatement / Hospital de la Princesa. UAM. / Spain
1993 - 1995	Associate Researcher / Duke University. Medical Center, NC, U.S.A. / United States of America
1991 - 1993	Postdoctoral Fellow / Duke University. Medical Center, NC, U.S.A. / United States of America
1987 - 1991	Postdoctoral Fellow / Fundación Jiménez Díaz / Spain

### A.3. Education

Degree/Master/PhD	University / Country	Year
Doctorado en Ciencias Biológicas	Universidad Autónoma de Madrid / Spain	1988

### A.4. General quality indicators of scientific production

Continuous and overlapping funding from the beginning as Principal Investigator obtained in calls in competition systems (MINECO or AES) and others.

Direction of 17 doctoral theses and master's thesis.

Total citations: 3008, citations since 2006: 1312.

Total number of journals in Q1 are 35. The 4 most cited publications add a total of more than 1500 citations and correspond to works on the current research topic on the function of the CD69 molecule. The original published scientific papers have an average impact factor of 7, which corresponds to the distribution of contribution as last author 40%, as first author 23% and as collaborator 37%.

## Part B. CV SUMMARY

Since 1999, the beginning of my research group in Barcelona, in addition to giving theoretical and practical teaching in immunology of various undergraduate, graduate, master and doctorate subjects, I have led a research group in Basic and Applied Immunology with a special interest in biotechnology, making important contributions to the study of the function and of CD69 in inflammation and infection models that includes the production and use of these monoclonal antibodies and the study of their gene regulation. In 2006 I moved my laboratory to the ISCIII in Madrid, continuing with the same lines of research and expanding the research to studies of new technologies for manufacturing and optimizing tissues, mainly using the skin as a model system. High quality scientific publications have been obtained, deriving several patents and being one of the publications distinguished in 2003 with the first prize "Ramón Margalef" for the best work published in the previous 5 years at the U. de Barcelona.

Experience supervising doctoral thesis and thesis and another thesis 17: 8 doctoral thesis, 5 TFM and 4 TFG.

Other merits:

Coordinator from 2014 to 2020 of the Immunology in the Master's Degree in Microbiology applied to public health and research in infectious diseases.

Professor from 2014 to the present of the Immunology in the Master's Degree in Microbiology applied to public health and research in infectious diseases. UAH-ISCIII.

## Part C. RELEVANT ACCOMPLISHMENTS

### C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Jennifer Redondo-Antón; Moguel G Fontela; Laura Notario; Raul Torres-Ruiz; S Rodríguez-Perales; Elena Lorente; (AC). (7/7). 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression *Frontiers in genetics*. 11-552949. <https://doi.org/10.3389/fgene.2020.552949>
- 2 **Scientific paper.** Elena Lorente; Miguel G. Fontela; Eilon Barnea; et al; ;. (8/9). 2020. Modulation of Natural HLA-B\*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). *Molecular & Cellular Proteomics*. 19-6, pp.994-1004. <https://doi.org/10.1074/mcp.RA120.002014>
- 3 **Scientific paper.** Elena Lorente; J Redondo-Antón; A Martín-Esteban; P Guasp; E Barnea; Pilar Lauzurica; A Admon; Jose Antonio Lopez de Castro. (8/10). 2019. Substantial Influence of ERAP2 on the HLA-B\*40:02 Peptidome: Implications for HLA-B\*27-Negative Ankylosing Spondylitis *Molecular & Cellular Proteomics*. 11, pp.2298-2309. <https://doi.org/10.1074/mcp.RA119.001710>
- 4 **Scientific paper.** Elena Lorente; AJ Martín-Galiano; E Barnea; et al; ;. (8/10). 2019. Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells. *Journal of proteome research*. 18, pp.900-911. <https://doi.org/10.1021/acs.jproteome.8b00595>
- 5 **Scientific paper.** Vanessa Helena Brait; Francesc Miro-Mur; Isabel Pérez de Puig; et al; ;. (18/19). 2019. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation *Circulation research*. 124-2, pp.279-291. <https://doi.org/10.1161/CIRCRESAHA.118.313818>
- 6 **Scientific paper.** Laura Notario Muñoz; Elisenda Alari-Pahissa; Almudena Albentosa; Magdalena Leiva; Guadalupe Sabio; (AC). (6/6). 2018. Anti-CD69 therapy induces rapid mobilization and high proliferation of HSPCs through S1P and mTOR *Leukemia*. 32-6, pp.1445-1457. <https://doi.org/s41375-018-0052-x>

- 7 **Scientific paper.** Laura Notario Muñoz; Elisenda Alari Pahissa; Antonio de Molina; et al; (AC). (10/10). 2016. CD69 deficiency enhances the host response to Vaccinia virus infection through altered NK cell homeostasis. *Journal of virology*. 90, pp.6464-6474. <https://doi.org/JVI.00550-16>
- 8 **Scientific paper.** Teresa Laguna; Laura Notario; R Pippa; et al; (AC). (10/10). 2015. New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence 2. *Molecular immunology*. 66-2, pp.171-179. <https://doi.org/j.molimm.2015.02.031>
- 9 **Scientific paper.** LK Mackay; JZ Ma; AT Collins N Stock; et al; ;. (6/13). 2013. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. *Nat Immunol*. 14-12, pp.1294-1301. <https://doi.org/10.1038/ni.2744>
- 10 **Scientific paper.** Andres Barbosa; Eva de Mas; Jesus Benzal; et al; ;. (10/12). 2013. Pollution and physiological variability in gentoo penguins at two rookeries with different levels of human visitation. *Antarctic Science*. 25-2, pp.329-338. <https://doi.org/10.1017/S0954102012000739>
- 11 **Scientific paper.** E Alari-Pahissa; L Notario; E lorente; J Vega-Ramos; A Justel; D Lopez; JA Villadangos; (AC). (8/8). 2012. CD69 does not affect the extent of T cell priming. *PLoS One*. 7-10, pp.e48593-158. <https://doi.org/10.1371/journal.pone.0048593>
- 12 **Scientific paper.** E Alari-Pahissa; J Vega-Ramos; JG Zhang; AR Castano; SJ Turley; JA Villadangos; (AC). (7/7). 2012. Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation. *J Leukoc Biol*. 92-1, pp.145-158. <https://doi.org/10.1189/jlb.1011499>
- 13 **Scientific paper.** BN Vazquez; T Laguna; L Notario; (AC). (4/4). 2012. Evidence for an intronic cis-regulatory element within CD69 gene. *Genes and immunity*. 13-4, pp.356-362. <https://doi.org/10.1038/gene.2012.4>
- 14 **Scientific paper.** J Kezerho; ED Yu; CM Barra; et al; (AC);. (7/11). 2012. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. *J. Immunol*. 188-5, pp.2254-2265. <https://doi.org/10.4049/jimmunol.1103049>
- 15 **Scientific paper.** J Vega-Ramos; E Alari-Pahissa; JD Valle; E Carrasco-Marin; E Esplugues; M Borrás; C Martínez-A; (AC). (8/8). 2010. CD69 limits early inflammatory diseases Associated with immune response to *Listeria monocytogenes* infection. *Immunology and Cell Biology*. 88-7, pp.707-715. <https://doi.org/10.1038/icb.2010.62>
- 16 **Scientific paper.** BN Vazquez; T Laguna; J Carabana; MS Krangel; (AC). (5/5). 2009. CD69 gene is differentially regulated in T and B cells by evolutionarily conserved promoter-distal elements. *J Immunol*. 183, pp.6513-6521. <https://doi.org/10.4049/jimmunol.0900839>
- 17 **Scientific paper.** David Sancho; Manuel Gomez; G Martínez del Hoyo; A Lamana; Enric Esplugues; Pilar Lauzurica; Carlos Martínez-A; Francisco Sánchez-Madrid. (6/8). 2006. CD69 targeting differentially affects the course of collagen-induced arthritis. *J Leuk Biol*. 80-6, pp.1233-1241. <https://doi.org/10.1189/jlb.1205749>
- 18 **Scientific paper.** I Saborit-Villarroya; JM del Valle; X Romero; E Esplugues; P Lauzurica; P Engel; M Martín. (5/7). 2005. The Adaptor Protein 3BP2 Binds Human CD244 and Links this Receptor to Vav Signaling, ERK Activation, and NK Cell Killing. *J Immunol*. 175, pp.4226-4235. <https://doi.org/10.4049/jimmunol.175.7.4226>
- 19 **Scientific paper.** Enric Esplugues; Javier Vega-Ramos; David Cartoixa; Berta N Vazquez; (AC); Pablo Engel; Pilar Lauzurica. (5/5). 2005. Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. *Blood*. 105, pp.4399-4406. <https://doi.org/10.1182/blood-2004-10-3854>
- 20 **Scientific paper.** D Sancho; M Gomez; F Viedma; et al; ;. (9/10). 2003. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. *J Clin Invest*. 112, pp.872-882. <https://doi.org/10.1172/JCI19112>
- 21 **Scientific paper.** Enric Esplugues; David Sancho; Carlos Martínez-A; Uta Syrbe; Alf Hamman; P Engel; F Sánchez-Madrid; (AC). (8/8). 2003. Enhanced antitumor immunity in mice deficient in CD69. *J. Exp Med*. 197, pp.1093-1106. <https://doi.org/10.1084/jem.20021337>

- 22 Scientific paper.** (AC); D Sancho; M Torres; et al;. (1/9). 2000. Phenotypic and Functional Characteristics of hematopoietic cell lineages in CD69-deficient mice *Blood*. 95, pp.2312-2320.
- 23 Scientific paper.** P Lauzurica; M Marazuela; P Gomez del Arco; AC Martinez; F Sanchez-Madrid; JM Redondo. (1/6). 1999. Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF-alpha. *Eur J. Immunol.* 29, pp.1890-1900. [https://doi.org/10.1002/\(SICI\)1521-4141\(199906\)29:06<1890::AID-IMMU1890>3.0.CO;2-F](https://doi.org/10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F)
- 24 Scientific paper.** MS Krangel; C Hernandez-Munain; P Lauzurica; JL Roberts; M McMurry; X Zhong. (3/6). 1998. Developmental regulation of V(D)J recombination at the TCR alpha/delta locus *Immunological Reviews*. 165, pp.131-147. <https://doi.org/10.1111/j.1600-065x.1998.tb01236.x>
- 25 Scientific paper.** MT McCurry; C Hernandez-Munain; P Lauzurica; MS Krangel. (3/4). 1997. Enhancer Control of local accessibility to VDJ recombinase *Molecular and Cellular Biology*. 17, pp.4553-4861. <https://doi.org/10.1128/mcb.17.8.4553>
- 26 Scientific paper.** P Lauzurica; XP Zhong; MS Krangel; JL Roberts. (1/4). 1997. Regulation of T cell receptor delta gene rearrangement by CBF/PEBP2 *J. Exp Med.* 185, pp.1193-1201. <https://doi.org/10.1084/jem.185.7.1193>
- 27 Scientific paper.** JL Roberts; P Lauzurica; MS Krangel. (2/3). 1997. Developmental regulation of VDJ recombination by the core fragment of the T cell receptor alpha enhancer. *J. Exp Med.* 185, pp.131-140. <https://doi.org/10.1084/jem.185.1.131>
- 28 Scientific paper.** C Hernandez-Munain; P Lauzurica; MS Krangel. (2/3). 1996. Regulation of T cell receptor delta gene rearrangement by c-Myb. *J. Exp Med.* 183, pp.289-293. <https://doi.org/10.1084/jem.183.1.289>
- 29 Scientific paper.** P Lauzurica; MS Krangel. (1/2). 1994. Enhancer dependent and independent steps in the rearrangement of a human T cell receptor transgene *J. Exp Med.* 179, pp.43-45. <https://doi.org/10.1084/jem.179.6.1913>
- 30 Scientific paper.** P Lauzurica; MS Krangel. (1/2). 1994. Temporal and lineage-specific control of T cell receptor alpha/delta gene rearrangement by T cell receptor alpha and delta enhancers. *J. Exp Med.* 179, pp.1913-1921. <https://doi.org/10.1084/jem.179.1.43>
- 31 Scientific paper.** P Lauzurica; R Bragado; B Galocha; JA Lopez de Castro. (1/4). 1992. Asymmetric selection of T cell antigen receptor alpha- and beta-chains in HLA-B27 alloreactivity. *J. Immunol.* 148, pp.3624-3630.
- 32 Scientific paper.** AR Castano; P Lauzurica; N Domenech; JA Lopez de Castro. (2/4). 1991. Structural identity between HLA-A2 antigens differentially recognized by alloreactive cytotoxic T lymphocytes. *J Immunol.* 146, pp.2915-2920.
- 33 Scientific paper.** R Bragado; P Lauzurica; D Lopez; JA Lopez de Castro. (2/4). 1990. T cell receptor V beta gene usage in a human alloreactive response. Shared structural features among HLA-B27-specific T cell clones. *J. Ex Med.* 171, pp.1189-1204. <https://doi.org/10.1084/jem.171.4.1189>.
- 34 Scientific paper.** P Lauzurica; C Gurbindo; N Maruri; B Galocha; R Diaz; J Gonzalez; R Garcia; C Lahoz. (1/8). 1988. Olive (*Olea europaea*) pollen allergens. I. Inmunochemical characterization by immunobloting, CRIE and immunodetection by a monoclonal antibody. *Molecular Immunol.* 25, pp.329-335. [https://doi.org/10.1016/0161-5890\(88\)90028-4](https://doi.org/10.1016/0161-5890(88)90028-4).
- 35 Scientific paper.** P Lauzurica; N Maruri; B Galocha; et al;. (1/9). 1988. Olive (*Olea europaea*) pollen allergens. II. Isolation and characterization of two major antigens. *Molecular Immunol.* 25, pp.337-344. [https://doi.org/10.1016/0161-5890\(88\)90028-4](https://doi.org/10.1016/0161-5890(88)90028-4)
- 36 Scientific paper.** Thiago Alves da Costa; Jacob N Peterson; Julie Lang; et al;. 2021. Central human B cell tolerance manifests with a distinctive cell phenotype and is enforced via CXCR4 signaling in hu-mice *Proceedings of the National Academy of Sciences. National Academy of Sciences.* 118-16.
- 37 Scientific paper.** Andres Marquez; Miguel Gómez-Fontela; Sara Lauzurica; et al; (AC);. (9/10). 2020. Fluorescence enhanced BA-LIFT for single cell detection and isolation *Biofabrication.* 12-025019. <https://doi.org/10.1088/1758-5090/ab6138>

- 38 **Scientific paper.** Laura Notario; Jennifer Redondo-Antón; Elisenda Alari-Pahissa; Almudena Albentosa; Magdalena Leiva; Daniel Lopez; Guadalupe Sabio; (AC). (8/8). 2019. CD69 Targeting Enhances Anti-vaccinia Virus Immunity Journal of virology. 93. <https://doi.org/10.1128/JVI.00553-19>
- 39 **Scientific paper.** Miguel G Fontela; Laura Notario; Elisenda Alari-Pahissa; Elena Lorente; (AC). (5/5). 2019. The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1. Genes. 10. <https://doi.org/10.3390/genes10090651>
- 40 **Scientific paper.** JA Lopez de Castro; R Bragado; P Lauzurica; S Rojo. (3/4). 1990. T cell receptor V beta gene usage in a human alloreactive response. Shared structural features among HLA-B27-specific T cell clones. Scand. J. Supp Rheumatology. 87, pp.21-31. <https://doi.org/10.3109/03009749009097054>
- 41 **Scientific paper.** C Gurbindo; L Tricas; P Lauzurica; V Urena; R Garcia; C Lahoz. (3/5). 1985. T cell dependence of human IgE response. Quantitative and functional studies Int Arch Allergy and Immunol App. 77, pp.445-450. <https://doi.org/10.1159/000233824>
- 42 **Scientific paper.** R Garcia; J Sastre; P Lauzurica; L Tricas; C Gurbindo; C Lahoz. (3/6). 1984. Transmethylation reactions in human basophils induced by anti-IgE or specific antigen. Int Arch Allergy Immunol and App. 73, pp.237-241. <https://doi.org/10.1159/000233474>

## C.2. Conferences and meetings

- 1 Pilar Lauzurica Gomez. Transcriptional regulation of CD69 gene through the enhancer located in the conserved non-coding sequence (CNS)2. 39 CONGRESO SEBBM 2016. Sociedad Española de Bioquímica y Biología Molecular. 2016. Spain.
- 2 Laura Notario Muñoz; Antonio de Molina; Pilar Lauzurica Gomez. AUGMENTED RESPONSE TO VACCINIA VIRUS IN CD69 DEFICIENT MICE. 11th EFIS-EJI Tatra Immunology conference. 2014. Slovakia.
- 3 Laura Notario Muñoz; Almudena Albentosa; Pilar Lauzurica Gomez. CD69 TARGETING CONTROL THE RESPONSE TO VACCINIA VIRUS INFECTION. 11th EFIS-EJI Tatra Immunology conference. 2014. Slovakia.
- 4 Teresa Laguna Lobo; et al.; Pilar Lauzurica Gomez. RUNX transcription factors regulate the transcriptional activity of CD69. International Congress of Immunology. 2013. Italy.
- 5 Javier Vega Ramos; et al.; Pilar Lauzurica Gomez. CD69 deficient mice: anti tumor response. Keyston Meeting in immunology. 2004. France.
- 6 Javier Vega Ramos; et al.; Pilar Lauzurica Gomez. CD69 deficient mice: anti tumor response. European Immunology Congress. 2003. France.
- 7 Javier Vega Ramos; et al.; Pilar Lauzurica Gomez. CD69 deficient mice: immune response to Listeria. European Immunology Congress. 2003. France.
- 8 et al.; Pilar Lauzurica Gomez. CD69 deficient mice. Marsella Immunology forum. 1998. France.
- 9 et al.; Pilar Lauzurica Gomez. Reordenamiento VDJ. Keystone meeting. 1997. United States of America.
- 10 et al.; Pilar Lauzurica Gomez. Reordenamiento VDJ. Keystone meeting. 1993. United States of America.
- 11 et al.; Pilar Lauzurica Gomez. Reconocimiento alotipico anti-HLA B-27: análisis de repertorio de TCRs. Nacional de Inmunología. 1989. Spain.
- 12 et al.; Pilar Lauzurica Gomez. Olea Europea. Internacional de Alergología e Inmunología. 1985. United States of America.
- 13 et al.; Pilar Lauzurica Gomez. Olea Europea. Nacional de Inmunología. 1983. Spain.
- 14 et al.; Pilar Lauzurica Gomez. Olea Europea. Nacional de Inmunología. 1983. Spain.

## C.3. Research projects and contracts

- 1 **Project.** Estudio de CD69 como diana para mejorar el tratamiento de la leucopenia y la movilización de células T memoria de médula ósea. (Instituto de Salud Carlos III). 01/01/2020-31/12/2022. 120.000 €.

- 2 **Project.** P2018/BAA-4480, Nuevas Tecnologías de Fabricación y Optimización de Tejidos: La Piel como Sistema Modelo. Comunidad de Madrid. Pablo Acedo. (Instituto de Salud Carlos III). 01/01/2019-31/12/2022. 761.753,56 €. Principal investigador.
- 3 **Project.** MPY 1346/16, Función de CD69 y sus elementos reguladores.. Instituto de Salud Carlos III. Pilar Lauzurica Gomez. (Instituto de Salud Carlos III). 01/01/2016-30/06/2021. 249.584 €. Co-ordinator. Investigadora Principal: responsable de la idea, escritura, presentación y realización del proyecto.
- 4 **Project.** PI13/01557, Análisis de los efectos de CD69, independiente, así dependiente de S1P1 en modelos de inflamación y la infección y el estudio de su regulación. Instituto de Salud Carlos III. Pilar Lauzurica Gomez. (Instituto de Salud Carlos III). 01/01/2013-01/12/2016. 120.000 €. Co-ordinator. Investigadora Principal: responsable de la idea, escritura, presentación y realización del proyecto. En la actualidad únicamente hay 2 miembros en el equipo.
- 5 **Project.** SAF2010-15649, Molecular and functional characterization of the regulatory role of the leukocyte receptor CD69 and its epigenetic regulation.. Ministerio de Ciencia e Innovación. Investigación. Pilar Lauzurica Gomez. (Instituto de Salud Carlos III). 01/01/2010-31/12/2013. 121.000 €. Co-ordinator. Investigador principal: responsable de la idea, redacción, presentación y ejecución. El equipo estaba formado por personal realizando su tesis doctoral.
- 6 **Project.** Innate and adaptive immune response regulated by the CD69 molecule: Infection and tumors. Ministerio de Ciencia y Tecnología. Pilar Lauzurica Gomez. (Instituto de Salud Carlos III). 2007-2010. 174.240 €. Co-ordinator. Investigador principal: responsable de la idea, redacción, presentación y ejecución. El equipo estaba formado por personal realizando su tesis doctoral.
- 7 **Project.** A new strategy of immune regulation of tumor growth based on the molecule CD69 as a target.. Fundacion La Marato de TV3". Pilar Lauzurica Gómez. (Universitat de Barcelona). 2005-2008. 230.000 €. Co-ordinator.
- 8 **Project.** SAF2005-04876, Role of the CD69 molecule in processes of innate and adaptive regulation: divergent role in infectious and antitumor responses.. Ministerio de Ciencia y Tecnología. Pilar Lauzurica Gomez. (Universitat de Barcelona). 2005-2006. 150.000 €. Co-ordinator.
- 9 **Project.** Study of the role of CD69 as a regulator of the immune response in model CD69-/- against tumors and infectious agents. M.C.yT.. SAF2002-02895. Pilar Lauzurica Gomez. (Universitat de Barcelona). 2002-2005. 165.500 €. Investigador principal: responsable de la idea, redacción, presentación y ejecución. El equipo estaba formado por personal realizando su tesis doctoral.
- 10 **Project.** SAF 1999-0034-C02-02, Regulation of the immune response by the activation molecule CD69: study in the mouse model CD69 (- / -). M.E.C.. (Universitat de Barcelona). 1999-2002. 165.500 €. Co-ordinator. Investigador principal de un subproyecto: responsable de la idea, redacción, presentación y ejecución. El equipo estaba formado por el IP y un estudiante realizando su tesis doctoral.
- 11 **Contract.** The role of the CD69 molecule in leukocyte activation and inflammatory immune responses 01/2006-01/01/2010.
- 12 **Contract.** Study of the role of lectin molecules induced after activation Pilar Lauzurica. 09/2005-30/11/2007.
- 13 **Contract.** Regulation by the CD69 activation molecule of the alloreactive response in hematopoietic transplants: Study in the mouse model CD69 (- / -), and intervention with anti-CD69 monoclonal antibodies 09/2000-28/02/2002.

#### C.4. Activities of technology / knowledge transfer and results exploitation

- 1 Laura Notario Muñoz; Pilar Lauzurica Gómez. 201730207. Uso de moduladores de la función de CD69 para la movilización y proliferación de precursores hematopoyéticos Spain. 20/09/2018. INSTITUTO DE SALUD CARLOS III.
- 2 Pilar Lauzurica; Francisco Sánchez-Madrid; Carlos Martínez-Alonso; David Sancho; Pablo Engel; Javier Vega. US 20110165071. Immune regulation based on the depletion of CD69+ cells. Methods of treating cancer. United States of America. 01/07/2011. FUNDACION GENERAL DE LA UNIVERSIDAD AUTONOMA DE MADRID FUAM. Albor Biologics (USA).

- 3 Pilar Lauzurica; Francisco Sánchez-Madrid; Carlos Martínez-Alonso; David Sancho; Pablo Engel; Javier Vega. US 20110081292. Immune regulation based on the depletion of CD69+ cells. Methods of treating viral hepatitis. United States of America. 01/04/2011. FUNDACION GENERAL DE LA UNIVERSIDAD AUTONOMA DE MADRID FUAM. Albor Biologics (USA).
- 4 Pilar Lauzurica; Francisco Sánchez-Madrid; Carlos Martínez-Alonso; David Sancho; Pablo Engel; Javier Vega. US 7867475. Immune regulation based on the depletion of CD69+ cells. United States of America. 01/01/2011. FUNDACION GENERAL DE LA UNIVERSIDAD AUTONOMA DE MADRID FUAM. US 7867475.
- 5 Pilar Lauzurica G3mez; Enric Esplugues Artola; Javier Vega Ramos; David Sancho Madrid; Francisco Sanchez Madrid; Carlos Martinez Alonso; Pablo Engel Rocamora; Dr; Dr. 2003002587. Patente de adici3n a la patente: "una nueva estrategia de regulaci3n inmune fundamentada en la mol3cula inducible durante la activaci3n leucocitaria CD69 Spain. 2005. UAM / CSIC and Pilar Lauzurica. ALBOR Inc; Bristol Meyers.
- 6 Pilar Lauzurica G3mez; Francisco Sanchez Madrid; Carlos Martinez Alonso; Pablo Engel Rocamora; Javier vega Ramos; Enric Esplugues Artola; David Sancho. 200300252. "A NEW STRATEGY of immune regulation based on MOLECULE CD69 inducible during leukocyte activation" and "improvements in PATENT Spain. 31/01/2004. UAM / CSIC and Pilar Lauzurica. ALBOR Inc.

#### **C.5. Stays in public or private R&D centres**

- 1 Instituto de Salud Carlos III. Centro Nacional de Microbiologia. Spain. Madrid. 2006-2012. 6 years. Contracted.
- 2 Universitat de Barcelona. Departament de Fisiologia, Fac. de Biologia. Spain. Barcelona. 1996-2006. 11 years. Contracted.
- 3 University of Humbolt. . Germany. Berlin. 2001-2001. 1 month - 7 days. Guest.
- 4 Hospital de la Princesa. UAM.. Departamento de Inmunologia. Spain. Madrid. 1995-1997. 2 years. Post-doctoral.
- 5 Duke University. Medical Center, NC, U.S.A.. Department of Immunology. United States of America. Durham. 1991-1995. 5 years. Post-doctoral.
- 6 Fundaci3n Jim3nez D3az. Department of Immunology. Spain. Madrid. 1988-1991. 4 years. Post-doctoral.